Edwards Lifesciences Q3 EPS rises 6% to $0.53; Q3 net sales climb 11% to $1.72 billion

PUBT · 15h ago
Edwards Lifesciences Q3 EPS rises 6% to $0.53; Q3 net sales climb 11% to $1.72 billion
  • Edwards Lifesciences’ third-quarter 2026 diluted earnings per share rose 6% year-over-year to $0.53.
  • Net sales climbed 11% year-over-year to $1.72 billion.
  • Impairment charges for intangible and long-lived assets increased to $220.2 million.
  • The FDA approved PASCAL Precision for tricuspid regurgitation in October, expanding patient access to the therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104708591) on November 04, 2026, and is solely responsible for the information contained therein.